Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

From 1949 to 1951, a controlled trial of BCG vaccinations was conducted in Puerto Rico. The 191,827 children, 1-18 years of age, initially enrolled in the study were skin-tested with tuberculin to determine their eligibility for vaccination. A total of 82,269 children were classified as reactors and not vaccinated. Of the 109, 558 nonreactors, 31,586 refused vaccination, 50,634 were vaccinated with BCG, and 27,338 were left unvaccinated as controls. We ascertained the incidence of cancer over an average follow-up period of 23.3 years in the latter two groups using the Puerto Rico Central Cancer Registry. By the end of December 1973, a total of 77 cancers had been diagnosed among the controls and 150 among the vaccinees. The overall incidence of cancer among the two groups was similar. Although a number of differences existed between the vaccinee group and the controls in regard to the incidence of cancer at various "sites", none of these differences was statistically significant. However, when cases of lymphosarcoma and Hodgkin's disease were combined for analysis, a statistically significant excess of cases occurred among the vaccinees. We concluded that BCG vaccination had no protective effect on the subsequent development of cancer in this population. The slight excess of cases of lymphosarcoma and Hodgkin's disease among the vaccinees raised the possibility that BCG may have had an adverse effect.
 ...
PMID:Efficacy of BCG vaccination in prevention of cancer: an update. 34 99

In May 1972, the Cancer and Leukemia Group B initiated a randomized study comparing the effectiveness of CCNU and methyl-CCNU in patients with advanced malignant lymphomas, including Hodgkin's disease (HD), lymphosarcoma (LYS) and reticulum cell sarcoma (RCS). A single dose of 100 mg/m2 of CCNU or 150 mg/m2 of methyl-CCNU was given orally every 6 weeks. In patients with leukopenia or thrombocytopenia, due to prior treatment, this dose was reduced to 70 mg/m2 of CCNU and 100 gm/m2 of methyl-CCNU. Of 109 evaluable patients, 60 received CCNU and 49 received methyl-CCNU. Response rates (complete and partial) to CCNU and methyl-CCNU were respectively 42% (14/33) and 15% (3/20) in HD, 21% (3/14) and 21% (3/14) in LYS, 15% (2/13) and 27% (4/15) in RCS. Responses to methyl-CCNU, but not to CCNU, were seen only in patients who developed significant hematologic toxicity. Responses to both drugs were generally of short duration due to the advanced stage of the disease. Renal, hepatic or neurological toxicity was not observed. In conclusion, CCNU proved to be superior to methyl-CCNU for the treatment of advanced HD. CCNU was also observed to be of higher activity in Hodgkin's than in non-Hodgkin's lymphomas.
 ...
PMID:Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma. 34 94

In 15 cases, chromosome studies were performed in short-term lymph node cultures, using the banding technique. Clonal aberrations were found in two cases of Hodgkin's disease and in two of lymphosarcoma. In agreement with earlier observations, the cases of lymphosarcoma with abnormal karyotypes proved hyperdiploid. No chromosomal aberrations were found in three cases of reactive lymphoreticular hyperplasia.
 ...
PMID:Chromosomes in malignant lymphomas (study on short-term lymph node cultures). 35 53

Monocytopoietic proliferation activity was investigated in patients with untreated Hodgkin's disease, Hodgkin's disease in long-term complete remission, and untreated non-Hodgkin's lymphoma of the lymphosarcoma and reticulosarcoma type. Untreated Hodgkin's disease was found to be associated with a rise in medullary monocyte production which returned to normal during long-term complete remissions. In contrast, monocyte production was increased in only 5 out of 14 patients with lymphosarcoma and reticulum cell sarcoma, normal in 3, and reduced in 6. In neither of these lymphomas was any relation between monocyte production and stage or histology of the disease detectable.
 ...
PMID:Monocyte production in Hodgkin's disease and non-Hodgkin's lymphoma. 35 66

Of 2907 bone marrow aspirations in patients with various malignancies, 192 or 6.6% exhibited 'dry tap'. In about 80% of the 'dry tap' there was material present inside the bone marrow needle which gave smears useful for evaluation of the bone marrow cytology. About 23% displayed normal cytology. Bone marrow involvement could be diagnosed in 13 out of 55 'dry tap' in Hodgkin's disease, 41 out of 46 in chronic lymphocytic leukaemia and lymphosarcoma, 6 out of 20 in reticulum cell sarcoma, 6 out of 9 in myelomatosis and 20 out of 45 in carcinoma. In a material of 174 aspirations with tumour cells in the bone marrow aspirate, the highest incidence of 'dry tap' was found in patients with Hodgkin's disease and patients with carcinoma, the lowest incidence in patients with multiple myeloma.
 ...
PMID:Incidence of 'dry tap' on bone marrow aspirations in lymphomas and carcinomas. Diagnostic value of the small material in the needle. 38 44

In vitro production of interferon by blood leukocytes from patients with lymphosarcoma, lymphogranulomatosis, leukemia, cancer tumours, pneumonia, as well as by leukocytes of mice with Rauscher leukemia, and mice in the condition of hyporeactivity to interferon inducer was studied. Alongside with quantitative differences in interferon production, biological differences in the properties of interferons produced of normal and sick humans and animals were revealed. The biological differences consist in that the interferon produced by leukocytes from cancer and leukemia patients interacting with homologous cell culture is conducive to more rapid formation of resistance to the indicator virus than the interferon produced by normal leukocytes. Thus, resistance of the homologous cell culture to the infection with the indicator vesicular stomatitis virus developed within 1--2 hours after contact with leukocyte interferon from patients and only within 5--6 hours after contact with that of normal subjects. This finding is not specific for cancer and leukemia, as the same was observed with specimens from patients with pneumonia and from mice hyporeactive to interferon inducer. It is suggested that patients with cancer and leukemia have a state of interferon hyporeactivity.
 ...
PMID:[Differences in the properties of the interferons produced by the leukocytes of healthy persons and of cancer and leukemia patients]. 50 7

A case of a 49 year old patient suffering from ulcerative colitis and chronic hepatitis with cirrothic transformation is presented who under prolonged immunosuppressive treatment with azathioprine 50 mg daily and 10 mg daily of prednisone developed Hodgkins disease whose diagnosis was at the autopsy. The association between hepatic cirrhosis and lymphoproliferative disorders such as lymphosarcoma and lymphatic leukemia were already described (19,20). Recently, an article was published on a similar case to ours (23) in which the patient, suffering from chronic hepatopathy submitted to azathioprine and corticoids, developed Hodgkin's disease. The link between ulcerative colitis, the chronic hepatopathy and the development of Hodgkin's disease that could have arisen as a consequence of the prolonged immunosuppressive treatment are discussed. The apparition of malignancies in patients submitted to immunosuppression owing to renal transplantation are compared with the apparition of malignancies in patients submitted to immunosuppression because of a number of other diseases.
 ...
PMID:[Hodgkin's disease developing in the course of a chronic liver disease with ulcerative colitis immunosuppressed with azathioprine]. 50 43

Glycylproline p-nitroanilidase activity in serum of patients with acute lymphatic leukemia, lymphosarcoma and Hodgkin's disease, and of normal neonates (umbilical blood) was significantly lower than that of normal adult controls. In contrast, the enzyme activity of patients with myelocytic leukemias did not differ significantly from that of normal controls.
 ...
PMID:Serum glycylproline p-nitroanilidase activity in blood cancers. 57 37

The application of low-dose segmental or total body irradiation to patients with generalized malignant non-Hodgkin lymphoma is discussed. The indications and irradiation procedure are presented in the light of a case report of a patient with generalized intra-abdominal lymphosarcoma and no evidence of disease 5 years after treatment.
 ...
PMID:[The value of low-dose segmental or total body irradiation in generalized disease of the lymphoreticular system: a case report (author's transl)]. 58 15

Of 47 children with an initial diagnosis of lymphosarcoma, reticulosarcoma or Non-Hodgkin's lymphoma (NHL), 13 had to be excluded at the histologic reevaluation: in 10 an undifferentiated sarcoma, in 2 Hodgkin lymphoma was found; in one patient no definite classification of the tumor was possible. Of the remaining 34 patients there were 26 boys and 8 girls. One patient had a nodular, 33 a diffuse NHL. Of the latter 16 had a Burkitt-type (LB-), 3 a lymphoblastic, convoluted (LC-), 8 a lymphoblastic, "other" (LO-) and 6 a histiocytoid (H-) NHL. Primary localization: abdomen: 13/34; "peripheral" lymph nodes: 9/34; mediastinum: 5/34; nasopharynx: 4/34; subcutis: 2/34; skeleton: 1/34. Twelve of 17 NHL with primary localization in the abdomen or nasopharynx were LB-NHL, 8/14 NHL with primary localization in "peripheral" nodes or mediastinum were LC- or LO-NHL. Only 2/17 NHL with abdominal or nasopharyngeal primary, but 9/14 NHL with "peripheral" nodal or mediastinal primary developed leukemic extension and/or CNS involvement. 6 of 34 patients are living without evidence of disease for 1 1/2+ to 13+ years; 5/34 died but lived for 85, 57, 37, 22 and 22 months; 9/34 lived 6--12 months; 14/34 died within less than 6 months. Patients with abdominal primary either died within 5 months or survived (for 165+, 63+ and 25+ months). Aggressive local therapy (surgery and radiotherapy with approximately 4000 R) may be adequate for strictly localized (stage I) disease, particularly if the primary localization is abdominal. In all other diffuse NHL of childhood an early, aggressive chemotherapy, later combined with radiotherapy to bulk disease and prophylactic CNS-treatment is essential for inducing long-term remissions and, possibly, cures. For prognosis the primary localization appeared to be more important than histology and stage. The most decisive factor, however, is therapy.
 ...
PMID:Malignant non-Hodgkin's lymphoma (NHL) in childhood. Retrospective analysis of 34 cases. 61 79


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>